Orphan Market Access

Orphan Medicine Market Access in Europe


On Thursday 28th September, our Managing Directors and Market Access Experts Dr Paul Craddy and Dr Graham Foxon hosted a live webinar, to discuss orphan medicine market access and the growing challenges ahead.

The webinar includes discussions on:
  • How rare diseases and orphan medicine will be impacted by the EU HTA.
  • The impact of HUMN legislation on European market access.
  • Comparing and contrasting different access strategies for orphan drugs.
  • Parallel scientific advice.

To view the webinar on demand, please click below.

If you have any questions or would like to discuss the topic in more detail, please reach out.

View our other webinars:

View our courses:

Strategic Market Access Planning for Orphan Drugs

Treatments for Orphan and Rare Disease offer attractive business opportunities to pharma, but the path to patient access is paved with many challenges. To optimise orphan medicine market access, companies need to carefully plan and execute their market access development strategy, as well as the evidence base and the value proposition.

Find out more here

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.